Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fanconi anemia group I protein (FANCI)
- Target
- FANCI
- Molecular classification
- DNA repair protein, member of the Fanconi anemia core complex, not a receptor or enzyme but functions as a genome stability factor
01
Overview
Fanconi anemia group I protein (FANCI) is essential for the repair of interstrand DNA cross-links and double-strand DNA breaks, forming part of the Fanconi anemia core complex involved in genome maintenance. FANCI works as a heterodimer with FANCD2, and together they are monoubiquitinated by the FA core complex in response to DNA damage. Monoubiquitinated FANCI–FANCD2 localizes to damaged chromatin, recruiting and organizing downstream DNA repair proteins to sites of replication blocks and DNA crosslinks. FANCI also functions in ribosomal RNA processing in the nucleolus and is essential for ensuring proper homologous recombination during meiosis. Mutations in FANCI lead to Fanconi anemia, characterized by increased chromosomal instability, susceptibility to malignancies, and bone marrow failure.
- Other names
- KIAA1794Fanconi anemia complementation group I proteinFA complementation group I protein
02
Mechanism of action
For DNA crosslinking drugs, mechanism is synthetic lethality: DNA crosslinkers cause lesions that require FA pathway for repair; FANCI-deficient cells are hypersensitive to these drugs
03
Biological functions
DNA repair (particularly interstrand cross-link repair and double-strand break repair)Maintenance of chromosomal stabilityCell cycle checkpoint activation (S phase and G2 upon DNA damage)Ribosome biogenesis (processing of pre-rRNA, involvement in nucleolus)Meiotic recombination (in germ cells)
04
Disease associations
Fanconi anemia (caused by germline mutations)Cancer (biallelic mutations confer increased cancer risk, especially hematological and solid tumors)Cytogenetic instability syndromes
05
Safety considerations
Deficiency leads to bone marrow failureimpaired hematopoiesiscancer predispositionTherapeutic challenges include genomic instabilityincreased toxicity to DNA-damaging treatmentsinfection riskpotential secondary malignancies
06
Interacting drugs
mitomycin C
1 more in the full profile.
07
Biomarkers
FANCI mutation/deletion status is used as a biomarker for Fanconi anemia diagnosis and can indicate sensitivity to DNA damaging chemotherapies
Beyond the preview
Go deeper on Fanconi anemia group I protein (FANCI).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fanconi anemia group I protein (FANCI).